RecruitingEarly Phase 1NCT06345898
Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)
Studying X-linked retinoschisis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- West China Hospital
- Principal Investigator
- Fang Lulufang@wchscu.cn
- Intervention
- JWK002(drug)
- Enrollment
- 12 target
- Eligibility
- 5-18 years · MALE
- Timeline
- 2023 – 2033
Study locations (1)
- West China Hospital, Chengdu, Sichuan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06345898 on ClinicalTrials.govOther trials for X-linked retinoschisis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06289452Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked RetinoschisisInnoVec Biotherapeutics Inc.
- RECRUITINGPHASE1, PHASE2NCT05878860ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisAtsena Therapeutics Inc.
- RECRUITINGNANCT05814952Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine